Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIROVA: Mirvetuximab Soravtansine in FRα High Recurrent Ovarian Cancer
NCT04274426Phase 2Active, not recruiting
- Sponsor
- AGO Research
- Start
- Oct 2021
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mirvetuximab soravtansine in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by AGO Research. Primary endpoint: Progression-Free Survival up to 2.5 years. Started Oct 2021; status: active, not recruiting.
02
Drugs
mirvetuximab soravtansine
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04274426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04274426.